CLAIMS:

1. A compound having the following formula:



(I)

wherein $R_1$ is selected from the following group consisting of:



,



, and



wherein $R_3$ is H or OH,

wherein $R_2$ is selected from the group consisting of



Methylenediphosphonate,



Difluoromethylenediphosphonate, and



Monofluoromethylenediphosphonate,

and wherein Cat+ represents one or more organic or mineral cations, comprising the proton, identical or different, in

the same compound, excepting 3-methyl-3-butene-1-yl-difluoromethylenediphosphonate, and 3-methyl-3-butene-1-yl-methylenediphosphonate.

2. The composition according to claim 1, wherein said compound is combination with an excipient or pharmaceutical additive.

3. A method for selectively inhibiting Tγ9δ2 lymphocytes, comprising:

contacting said Tγ9δ2 lymphocytes with an effective amount of the compound according to claim 1.

4. A method for treating a patient with a pathology that activates Tγ9δ2 lymphocytes, comprising:

administering to said patient in need thereof an effective amount of the compound according to claim 1.

5. A method for treating a primate with a pathology that activates Tγ9δ2 lymphocytes, comprising:

administering to said primate in need thereof an effective amount of the compound according to claim 1.

6. A method for treating parasitosis in a primate, comprising:

administering to said primate in need thereof an effective amount of the compound according to claim 1.

7. The method according to claim 6, wherein said parasitosis is selected from the group consisting of malaria, visceral leishmaniosis, toxoplasmosis.

8. A method for treating an autoimmune malady in a primate, comprising:

administering to said primate in need thereof an effective amount of the compound according to claim 1.

9. The method according to claim 8, wherein said malady is behcet malady.

10. A method for selectively inhibiting Tγ9δ2 lymphocytes in an extracorporeal medium, comprising:

contacting said Tγ9δ2 lymphocytes in said extracorporeal medium with an effective amount of the compound according to claim 1.

11. A method for inhibiting polyclonal proliferation of Tγ9δ2 lymphocytes, comprising:

contacting said Tγ9δ2 lymphocytes with an effective amount of the compound according to claim 1.